The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease |
| |
Authors: | J Susie Woo Jeffrey L Probstfield |
| |
Institution: | (1) Division of Cardiology, University of Washington Medical Center, 2815 Eastlake Avenue East, Suite 200, Seattle, WA 98102, USA |
| |
Abstract: | Pharmacologic attenuation of the renin-angiotensin-aldosterone system (RAAS) either through angiotensin-converting enzyme
(ACE) inhibition or angiotensin II receptor blockade now occupies a central role in the management of hypertension, diabetes,
heart failure, and cardiovascular and renal disease. Although our understanding and use of these agents has expanded significantly
over the past decade, the relative and differential benefits of ACE inhibitors and angiotensin receptor blockers (ARBs) are
still not entirely clear. The data continue to support the first-line use of ACE inhibitors for all indications. Results for
combination ACE inhibitor and ARB therapy in clinical outcome trials have been disappointing and do not support its use. New
strategies for RAAS modulation bring hope for further progress in the treatment of hypertensive and cardiovascular disease. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|